摘要
慢性粒-单核细胞白血病(chronic myelomonocytic leukemia,CMML)合并免疫性血小板减少症(immune thrombocytopenia,ITP)十分罕见。该文报告1例采用维奈克拉联合瑞帕妥单抗(一种抗CD20单克隆抗体)及海曲泊帕治疗CMML合并ITP患者的临床资料。CMML和ITP的共存机制需要进一步明确。维奈克拉联合抗CD20单抗及血小板生成素受体激动剂可能是治疗该合并症的有效策略之一。
Chronic myelomonocytic leukemia(CMML)complicated with immune thrombocytopenia(ITP)is rare.This article reports the clinical data of a patient with CMML complicated with ITP treated with a combination of venetoclax,ripertamab(an anti-CD20 monoclonal antibody),and hetrombopag.The coexistence mechanism of CMML and ITP needs to be further clarified.Venetoclax combined with anti-CD20 monoclonal antibody and thrombopoietin receptor agonist may be an effective strategy for the treatment of this complication.
作者
刘嘉榆
黄方
郝思国
LIU Jiayu;HUANG Fang;HAO Siguo(Department of Hematology,Xinhua Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200082,China)
出处
《上海交通大学学报（医学版）》
CAS
CSCD
北大核心
2024年第2期287-290,共4页
Journal of Shanghai Jiao tong University:Medical Science
